Clinical trial
A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies
NCT02222545 is registered in ClinicalTrials.gov with Omeros Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies
- Lead sponsor
- Omeros Corporation
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 2, 2014
- Completion date
- August 11, 2020
- Enrollment
- 58 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.